Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report-Reference-Cited by-同舟云学术

Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report

Published:2021-12 Issue:4 Volume:20 Page:364-367
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Calegari Maria Alessandra^ORCID,Stefano Brunella Di,Basso Michele,Carbone Carmine,Camarda Floriana,Ribelli Marta,Anghelone Annunziato,Vivolo Raffaella,Bensi Maria^ORCID,Martini Maurizio,Pozzo Carmelo,Vellone Maria,Ardito Francesco^ORCID,Salvatore Lisa,Giuliante Felice,Tortora Giampaolo

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference25 articles.

1. BRAF in metastatic colorectal cancer: the future starts now;Orlandi;Pharmacogenomics,2015

2. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis;Clancy;Colorectal Dis,2013

3. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases;Karagkounis;Cancer,2013

4. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases;Kawaguchi;Clin Cancer Res,2019

5. Is hepatectomy justified for BRAF mutant colorectal liver metastases?: a multi-institutional analysis of 1497 patients;Gagniere;Ann Surg,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cetuximab/encorafenib;Reactions Weekly;2022-02